{"id":"non-selective-nsaids","safety":{"commonSideEffects":[{"rate":"1-3%","effect":"Gastrointestinal bleeding or ulceration"},{"rate":"10-20%","effect":"Dyspepsia"},{"rate":"5-10%","effect":"Nausea"},{"rate":"1-2%","effect":"Increased cardiovascular events (MI, stroke)"},{"rate":"1-5%","effect":"Renal impairment"},{"rate":"5-10%","effect":"Hypertension"},{"rate":"5-10%","effect":"Headache"},{"rate":"3-5%","effect":"Dizziness"}]},"_chembl":{"chemblId":"CHEMBL5744861","moleculeType":null,"molecularWeight":"313.45"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Non-selective NSAIDs block cyclooxygenase (COX) enzymes, which are responsible for producing prostaglandins—key mediators of inflammation, pain, and fever. By inhibiting both COX-1 and COX-2 isoforms, these drugs reduce prostaglandin levels systemically. This broad inhibition provides analgesic and anti-inflammatory effects but also increases the risk of gastrointestinal and cardiovascular adverse events compared to selective COX-2 inhibitors.","oneSentence":"Non-selective NSAIDs inhibit both COX-1 and COX-2 enzymes to reduce prostaglandin synthesis, thereby decreasing inflammation, pain, and fever.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:36:24.046Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Mild to moderate pain"},{"name":"Rheumatoid arthritis"},{"name":"Osteoarthritis"},{"name":"Fever"},{"name":"Dysmenorrhea"},{"name":"Acute musculoskeletal pain"}]},"trialDetails":[{"nctId":"NCT06967363","phase":"","title":"Multimodal Imaging and Biospecimen Collection for Low Back Pain (LBPB)","status":"NOT_YET_RECRUITING","sponsor":"Peking University Third Hospital","startDate":"2025-05-15","conditions":"Chronic Low Back Pain (CLBP), Acute Low Back Pain, Low Back Pain","enrollment":360},{"nctId":"NCT06778824","phase":"NA","title":"Neuroregulators for the Treatment of Diseases Associated With Esophageal-brain-gut Axis Communication Abnormalities.","status":"RECRUITING","sponsor":"Hualien Tzu Chi General Hospital","startDate":"2024-04-02","conditions":"Gut-Brain Disorders, GERD Without Erosive Esophagitis","enrollment":610},{"nctId":"NCT06498440","phase":"PHASE4","title":"Efficacy of NSAID vs. Steroid-NSAID Combo Post-Selective Laser Trabeculoplasty: Phase 4, Single-Center RCT","status":"NOT_YET_RECRUITING","sponsor":"St. Joseph's Healthcare Hamilton","startDate":"2024-09-01","conditions":"Open Angle Glaucoma, Ocular Hypertension, Postoperative Inflammation","enrollment":126},{"nctId":"NCT04673578","phase":"PHASE2","title":"Adjunctive Celecoxib in Childhood-onset OCD Study","status":"UNKNOWN","sponsor":"University of British Columbia","startDate":"2021-06-01","conditions":"Obsessive-Compulsive Disorder, Pediatric Psychiatric Disorder","enrollment":80},{"nctId":"NCT01077843","phase":"","title":"Post-authorization Safety Study of Etoricoxib and Other Anti-inflammatory Therapies in European Patients With Ankylosing Spondylitis (MK-0663-163)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2009-08-17","conditions":"Ankylosing Spondylitis","enrollment":27381},{"nctId":"NCT03892707","phase":"","title":"Milgamma® and Milgamma® Compositum Step-therapy in Patients With Acute Non-specific Low Back Pain Receiving Modern NSAID","status":"COMPLETED","sponsor":"Woerwag Pharma LLC","startDate":"2018-12-15","conditions":"Acute Non-specific Low Back Pain","enrollment":500},{"nctId":"NCT00373685","phase":"PHASE4","title":"GI-Reasons- A Trial Of GI Safety Of Celecoxib Compared With Non-Selective Nonsteroidal Antiinflammatory Drugs (NSAIDS)","status":"COMPLETED","sponsor":"Pfizer's Upjohn has merged with Mylan to form Viatris Inc.","startDate":"2006-10","conditions":"Osteoarthritis","enrollment":8067},{"nctId":"NCT00446797","phase":"PHASE4","title":"Open Label Comparative Study On Celecoxib Efficacy And Safety Vs Non-Selective NSAID In Acute Pain Due To Ankle Sprain","status":"COMPLETED","sponsor":"Pfizer's Upjohn has merged with Mylan to form Viatris Inc.","startDate":"2007-05","conditions":"Ankle Sprain","enrollment":278},{"nctId":"NCT04008654","phase":"NA","title":"Evaluation of the Benefits of Enhanced Recovery After Surgery (ERAS) Protocol in Pelvic Prolapse","status":"COMPLETED","sponsor":"Kanuni Sultan Suleyman Training and Research Hospital","startDate":"2019-07-05","conditions":"Urinary Incontinence, Pelvic Organ Prolapse","enrollment":120},{"nctId":"NCT03986450","phase":"NA","title":"ERAS Protocol in Laparoscopic Hysterectomy","status":"UNKNOWN","sponsor":"Kanuni Sultan Suleyman Training and Research Hospital","startDate":"2019-06-20","conditions":"Surgery","enrollment":60},{"nctId":"NCT02550717","phase":"","title":"Epidemiological Study on the Safety of Aspirin in The Health Improvement Network (THIN)","status":"COMPLETED","sponsor":"Bayer","startDate":"2015-09-01","conditions":"Secondary Prevention, Stroke, Ischemic Heart Disease","enrollment":398158},{"nctId":"NCT03612323","phase":"EARLY_PHASE1","title":"Comparison Between Intraligamentary Piroxicam and Articaine","status":"UNKNOWN","sponsor":"Cairo University","startDate":"2018-11","conditions":"Pulpitis - Irreversible","enrollment":20},{"nctId":"NCT02625155","phase":"PHASE4","title":"Standard of Care Versus Urine Testing With Selective PHarmacogenomics for Effective Drug and Dosing REgimens","status":"UNKNOWN","sponsor":"InSource Diagnostics","startDate":"2015-12","conditions":"Target Drug-related Adverse Events","enrollment":14000},{"nctId":"NCT01058278","phase":"NA","title":"Impact Post-operative Treatment on Intraocular Pressure Post-SLT on Patients With Primary Open-angle Glaucoma","status":"COMPLETED","sponsor":"CHU de Quebec-Universite Laval","startDate":"2008-03","conditions":"Glaucoma, Inflammatory Response","enrollment":67},{"nctId":"NCT00828477","phase":"PHASE4","title":"Evaluation of Comfort With Xibrom (Bromfenac Ophthalmic Solution)0.09% and Nevanac (Nepafenac Ophthalmic Suspension) 0.1% Following Selective Laser Trabeculoplasty (SLT)","status":"COMPLETED","sponsor":"Bp Consulting, Inc","startDate":"2009-01","conditions":"Intraocular Pressure","enrollment":25},{"nctId":"NCT00524329","phase":"","title":"Esomeprazole And Symptomatic Response In Patients With Or Without An Elevated Risk For Non-Steroidal Anti-Inflammatory Drug (NSAID)-Associated GI Damage","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2006-01","conditions":"Heartburn","enrollment":1220}],"_emaApprovals":[],"_faersSignals":[{"count":1,"reaction":"ACCIDENT"},{"count":1,"reaction":"JOINT INJURY"},{"count":1,"reaction":"LUNG ADENOCARCINOMA"},{"count":1,"reaction":"METASTASES TO CENTRAL NERVOUS SYSTEM"},{"count":1,"reaction":"PLASMACYTOMA"}],"_approvalHistory":[],"publicationCount":319,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Non-selective NSAIDS","genericName":"Non-selective NSAIDS","companyName":"Pfizer's Upjohn has merged with Mylan to form Viatris Inc.","companyId":"pfizer-s-upjohn-has-merged-with-mylan-to-form-viatris-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Non-selective NSAIDs inhibit both COX-1 and COX-2 enzymes to reduce prostaglandin synthesis, thereby decreasing inflammation, pain, and fever. Used for Mild to moderate pain, Rheumatoid arthritis, Osteoarthritis.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}